Freddy Nguyen Featured on Pitt HexAI Podcast for Precision Medicine Innovation

Nine Diagnostics CEO and Co-Founder Freddy T. Nguyen, MD, PhD, appeared on Episode 40 of the Pitt HexAI Podcast to discuss AI-enabled cancer diagnostics and the entrepreneurship pathway behind Nine Diagnostics. The episode explores how molecular fingerprinting and multimodal AI are shifting oncology from static genomic snapshots toward real-time functional precision medicine.

Freddy Nguyen Featured on From Models to Medicine for Diagnostic AI Equity

Nine Diagnostics CEO and Co-Founder Freddy T. Nguyen, MD, PhD, joined KAMI Think Tank’s From Models to Medicine podcast for Episode 8, “The Equity Gap in Diagnostic AI,” a candid conversation on what equitable AI in medicine actually requires. The discussion examines where AI breaks down in clinical workflows, the equity implications of non-representative diagnostic datasets, and how the Nine Diagnostics multiomics platform approaches real-time treatment monitoring.

Nine Diagnostics Joins DRIVE Accelerator with SCbio and MassBio

Nine Diagnostics is participating in the Spring 2026 DRIVE Accelerator Biomarkers and Diagnostics track, a national program run by SCbio in partnership with MassBio supporting early-stage companies advancing next-generation diagnostic technologies. The program provides expert mentorship, curriculum, and access to strategic partners, including Eli Lilly and LabCorp, focused on accelerating clinical translation. Participation advances Nine Diagnostics’ positioning within the precision medicine ecosystem and builds pathways toward commercialization.

Nine Diagnostics Pitches at BioTools Innovator East Coast Road Tour

Nine Diagnostics participated in the BioTools Innovator East Coast Road Tour pitch event, a competitive selection process run by BioTools Innovator, the first accelerator focused exclusively on life science tools and diagnostics startups powered by MedTech Innovator. Nine Diagnostics presented its nanosensor-enabled, machine learning-driven approach to molecular fingerprinting and its potential for biomarker-agnostic diagnostics across challenging disease areas. The Road Tour brought together early-stage tools and diagnostics companies for evaluation by a panel of judges from leading industry partners including Thermo Fisher Scientific, BARDA, and Research Corporation Technologies.

Nine Diagnostics Selected to Present at FNIH Biomarkers Consortium 20th Anniversary Symposium

Nine Diagnostics was selected to present at the FNIH Biomarkers Consortium 20th Anniversary Symposium, a leading forum convening senior leaders across academia, industry, and government to advance biomarker science. The selection reflects growing recognition of the Nine Diagnostics platform and alignment with the field’s shift toward integrated, data-driven diagnostic approaches. Nine Diagnostics’ nanosensor and machine learning platform is directly positioned to support this transition, enabling complex molecular signatures that inform treatment decisions in oncology.

Heller and Kim Selected for ARPA-H LIGHT Program on Lymphatic Disease Diagnostics

Nine Diagnostics co-founders Daniel Heller and Mijin Kim are contributing to the ARPA-H LIGHT program as part of the Weill Cornell Medicine-led LANTERN team, one of 11 groups funded through a $135.7M federal initiative to advance lymphatic disease diagnostics. Heller and Kim are developing nanosensor-based detection technologies integrated with AI, building tools to measure and interpret molecular signals from the lymphatic system. This work advances a historically under-characterized area of biology with broad relevance to cancer, infectious disease, and immune disorders.

Nine Diagnostics and Orbits Oncology Launch Exploratory Partnership on Precision Oncology Platform

Nine Diagnostics and Orbits Oncology have entered into an exploratory partnership to jointly develop a next-generation precision oncology diagnostics platform. The collaboration pairs Nine Diagnostics’ nanosensor-based molecular fingerprinting, which captures systemic disease signals from blood, with Orbits’ AI-powered computer vision platform that analyzes patient-derived organoid microscope imagery to provide a more dynamic and clinically relevant picture of treatment response.

Nanosensor Liquid Biopsy Detects and Classifies Brain Tumors — Nature Nanotechnology

Nine Diagnostics co-founders Daniel A. Heller, PhD, and Mijin Kim, PhD, co-authored a cover article in Nature Nanotechnology (February 2026) demonstrating 98% accuracy in brain tumor detection and 71% accuracy in tumor type identification across 739 patients at Memorial Sloan Kettering Cancer Center, Northwestern University, and NYU. The study established the first multi-site clinical validation of quantum-defect-modified SWCNT arrays for cancer liquid biopsy, using a machine perception approach that detects tumors indirectly through the body’s systemic molecular response rather than requiring tumor material to cross the blood-brain barrier.

Nine Diagnostics Graduates from ACS BrightEdge Entrepreneurs Program

Nine Diagnostics graduated from the American Cancer Society BrightEdge Entrepreneurs Program, culminating in a Demo Day pitch presentation of the Nine Diagnostics nanosensor-enabled, machine learning-driven diagnostic platform. The 10-month program, run by BrightEdge, ACS’s impact investment and innovation arm, provided structured mentorship on scientific strategy, clinical translation, and early go-to-market planning, alongside access to oncology thought leaders and investors. Graduation marks a key milestone in Nine Diagnostics’ development, reinforcing the relevance of its platform and momentum toward clinical validation and deployment.

Nine Diagnostics Selected for Medical Alley Q3 Innovation Showcase

Nine Diagnostics presented at the Q3 Medical Alley Innovation Showcase on September 22, 2025, one of six companies selected to present within Minnesota’s health innovation ecosystem, one of the most concentrated healthcare networks in the country. The selection connected Nine Diagnostics with venture capital firms, strategic partners, and family offices actively investing in the next generation of health technology.